Growth Hormone Releasing Hormone 1-44
Isolated Congenital Growth Hormone Deficiency
Massachusetts General Hospitalprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Isolated Congenital Growth Hormone Deficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Serostim University of Calgary | Phase 4 | BBB |
Omnitrope University Hospital, Toulouse | Phase 4 | BB |
Tesamorelin Columbia University | Phase 4 | B |
Advicor Component Niacin Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1/2 | CCC |
Recombinant Gh Saizen Federico II University | Phase 3 | NR |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →